Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Nozomi Takada"'
Autor:
Nozomi Takada, Yasuharu Niwa, Tomoaki Teshigawara, Kazue Isogai, Hanayuki Okura, Akifumi Matsuyama
Publikováno v:
Regenerative Therapy, Vol 15, Iss , Pp 112-120 (2020)
In regenerative medical products for clinical applications, a major concern is the risk of ruminant-derived materials developing transmissible spongiform encephalopathy (TSE) in the manufacturing process. Because of the risk of TSE causing prion dise
Externí odkaz:
https://doaj.org/article/a61203d507314158a6cc08c50824bee6
Autor:
Takuya Kuroda, Satoshi Yasuda, Hiroyuki Nakashima, Nozomi Takada, Satoko Matsuyama, Shinji Kusakawa, Akihiro Umezawa, Akifumi Matsuyama, Shin Kawamata, Yoji Sato
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-12 (2017)
Abstract Human pluripotent stem cells (hPSCs) are leading candidate raw materials for cell-based therapeutic products (CTPs). In the development of hPSC-derived CTPs, it is imperative to ensure that they do not form tumors after transplantation for s
Externí odkaz:
https://doaj.org/article/0840e66561c64d6fbe8d79444de7b309
Autor:
Satoshi Yasuda, Shinji Kusakawa, Takuya Kuroda, Takumi Miura, Keiko Tano, Nozomi Takada, Satoko Matsuyama, Akifumi Matsuyama, Michiyo Nasu, Akihiro Umezawa, Takao Hayakawa, Hideki Tsutsumi, Yoji Sato
Publikováno v:
PLoS ONE, Vol 13, Iss 10, p e0205022 (2018)
Human induced pluripotent stem cells (hiPSCs) represent promising raw materials of human cell-based therapeutic products (hCTPs). As undifferentiated hiPSCs exhibit intrinsic tumorigenicity properties that enable them to form teratomas, hCTPs contain
Externí odkaz:
https://doaj.org/article/e05fc1f3ac01447fbc2ef9c5fa9e15af
Autor:
Shinji Kusakawa, Kazuhiko Machida, Satoshi Yasuda, Nozomi Takada, Takuya Kuroda, Rumi Sawada, Hanayuki Okura, Hideki Tsutsumi, Shin Kawamata, Yoji Sato
Publikováno v:
Regenerative Therapy, Vol 1, Iss C, Pp 30-37 (2015)
The contamination of human cell-processed therapeutic products (hCTPs) with tumorigenic cells is one of the major concerns in the manufacturing and quality control of hCTPs. However, no quantitative method for detecting the tumorigenic cellular impur
Externí odkaz:
https://doaj.org/article/c476e3b89b7a4be5b39447e6839d167d
Autor:
Naoki Nishishita, Masayuki Shikamura, Chiemi Takenaka, Nozomi Takada, Noemi Fusaki, Shin Kawamata
Publikováno v:
PLoS ONE, Vol 7, Iss 6, p e38389 (2012)
CD34+ cord blood cells can be reprogrammed effectively on dishes coated with a synthetic RGD motif polymer (PronectinF®) using a temperature sensitive Sendai virus vector (SeV TS7) carrying reprogramming factors OCT3/4, SOX2, KLF4 and c-MYC. Dish-sh
Externí odkaz:
https://doaj.org/article/fa2b918d537844da8d3b8962895a3054
Autor:
Naoki Nishishita, Masayuki Shikamura, Chiemi Takenaka, Nozomi Takada, Noemi Fusaki, Shin Kawamata
Publikováno v:
PLoS ONE, Vol 7, Iss 9 (2012)
Externí odkaz:
https://doaj.org/article/9e806819e8c0458494be1298e1732ba2
Autor:
Akifumi Matsuyama, Yasuharu Niwa, Hanayuki Okura, Tomoaki Teshigawara, Nozomi Takada, Kazue Isogai
Publikováno v:
Regenerative Therapy
Regenerative Therapy, Vol 15, Iss, Pp 112-120 (2020)
Regenerative Therapy, Vol 15, Iss, Pp 112-120 (2020)
In regenerative medical products for clinical applications, a major concern is the risk of ruminant-derived materials developing transmissible spongiform encephalopathy (TSE) in the manufacturing process. Because of the risk of TSE causing prion dise
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36aa35b8521a0cf7ee5f1f6315b87951
https://doi.org/10.1016/j.reth.2020.05.005
https://doi.org/10.1016/j.reth.2020.05.005
Autor:
Hanayuki Okura, Satoru Yoshida, Takaharu Negoro, Akifumi Matsuyama, Midori Maehata, Shigekazu Hayashi, Nozomi Takada
Publikováno v:
NPJ Regenerative Medicine
npj Regenerative Medicine, Vol 4, Iss 1, Pp 1-10 (2019)
npj Regenerative Medicine, Vol 4, Iss 1, Pp 1-10 (2019)
Definitive treatment of stroke constitutes an important thesis of regenerative medicine in the cerebrovascular field. However, to date, no cell therapy products for stroke are yet on the market. In this study, we examined the clinical research trends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24e8c72d5e9506aa3dd17ecf8664090f
https://pubmed.ncbi.nlm.nih.gov/31728206
https://pubmed.ncbi.nlm.nih.gov/31728206
Autor:
Akifumi Matsuyama, Hideki Tsutsumi, Takuya Kuroda, Satoko Matsuyama, Akihiro Umezawa, Shinji Kusakawa, Yoji Sato, Satoshi Yasuda, Takao Hayakawa, Michiyo Nasu, Takumi Miura, Nozomi Takada, Keiko Tano
Publikováno v:
PLoS ONE
PLoS ONE, Vol 13, Iss 10, p e0205022 (2018)
PLoS ONE, Vol 13, Iss 10, p e0205022 (2018)
Human induced pluripotent stem cells (hiPSCs) represent promising raw materials of human cell-based therapeutic products (hCTPs). As undifferentiated hiPSCs exhibit intrinsic tumorigenicity properties that enable them to form teratomas, hCTPs contain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::986637d034c85e73d85503143f5485a7
https://pubmed.ncbi.nlm.nih.gov/30286143
https://pubmed.ncbi.nlm.nih.gov/30286143
Autor:
Takuya Kuroda, Nozomi Takada, Shinji Kusakawa, Kazuhiko Machida, Hideki Tsutsumi, Rumi Sawada, Satoshi Yasuda, Yoji Sato, Shin Kawamata, Hanayuki Okura
Publikováno v:
Regenerative Therapy
Regenerative Therapy, Vol 1, Iss C, Pp 30-37 (2015)
Regenerative Therapy, Vol 1, Iss C, Pp 30-37 (2015)
The contamination of human cell-processed therapeutic products (hCTPs) with tumorigenic cells is one of the major concerns in the manufacturing and quality control of hCTPs. However, no quantitative method for detecting the tumorigenic cellular impur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::196066e7b263d2498ae8fc4807fbbd1b
https://doi.org/10.1016/j.reth.2014.12.001
https://doi.org/10.1016/j.reth.2014.12.001